Beyond GLP-1 — what actually moves body composition long-term.
If you stop a GLP-1 with no architecture beneath it, two-thirds of the weight comes back within twelve months. The architecture is the program. Drugs are one tool — peptides, hormones, sleep, training, and protein are the rest.
GLP-1s are powerful. They are not complete.
Modern incretin therapy is the most effective metabolic intervention ever made widely available. Tirzepatide produces 20% mean weight loss. Retatrutide will likely produce 28%. These numbers are real and worth respecting.
And yet — the real-world failure mode of GLP-1 therapy is not that the drugs don't work. It is that patients lose weight without an underlying architecture, stop the drug because of cost or side effects, and regain everything plus interest. The 12-month post-discontinuation regain in published trials is roughly two-thirds of total weight lost.
The fix is not "willpower." The fix is building the rest of the system while the drug is doing the heavy lifting. That's what this article is about.
What every Limitless weight-loss program contains.
Whether the patient is on tirzepatide, semaglutide, no drug, or a peptide-only protocol, these four pillars are non-negotiable. Drugs amplify what's underneath them. Without these pillars, drugs lose their leverage.
Lean-mass protection
Protein 1.6–2.2 g/kg ideal body weight. Resistance training 3×/week minimum. Creatine 5g daily. Without this, 25–35% of GLP-1 weight loss is lean tissue — unacceptable for longevity.
Hormone optimization
Testosterone, thyroid, cortisol screened and treated. Untreated hypogonadism caps weight loss in men. Subclinical hypothyroidism slows everything in women. Insulin and glucose optimized in parallel.
Sleep + circadian
7–8 hours of high-quality sleep. Sleep apnea screened and treated (tirzepatide's OSA indication is real). Cortisol and melatonin rhythm coached. No drug overcomes 5 hours of broken sleep nightly.
Exit + maintenance plan
Discontinuation strategy designed at intake — taper protocols, maintenance dosing, lifestyle anchors. We treat GLP-1s as ongoing therapy unless the patient explicitly chooses otherwise.
The peptides and adjuncts that layer with GLP-1 therapy.
These are the tools we deploy alongside (or sometimes instead of) GLP-1s, depending on the patient picture:
Tesamorelin
FDA-approved GHRH analog. Uniquely targets visceral adipose tissue (VAT) — the metabolically active fat that drives inflammation, insulin resistance, and CV risk. Falutz et al. (Phase 3) demonstrated statistically significant VAT loss at 26 weeks. The most evidence-supported peptide for body recomposition that GLP-1s do not specifically address. Layered onto GLP-1 therapy when scale weight is moving but visceral fat is not.
MOTS-c
Mitochondrial-derived peptide. Activates AMPK — the cellular energy sensor central to metabolic flexibility, insulin sensitivity, and endurance. Useful for patients with metabolic plateau, post-GLP-1 maintenance, or longevity-first goals. Returned to legal compounding April 23, 2026.
Sermorelin · Ipamorelin (GH-axis adjuncts)
Pulsatile GH-axis support layered on top of our tesamorelin lead. Restores natural GH rhythm lost with age. Improves sleep quality, recovery, and lean-mass preservation — particularly important during a GLP-1 cut. Without HGH-style supraphysiologic spikes or side effects. Why CJC-1295 is not on the menu →
NAD+ (IV + SubQ)
Dr. Hare's signature longevity intervention. NAD+ stores deplete with age and accelerate during caloric restriction. Loading protocol restores cellular NAD+ stores; subcutaneous maintenance keeps them there. Affects cognition, recovery, and the rate at which you age. Layered into nearly every Limitless protocol.
Testosterone Optimization (Men)
Testosterone deficiency caps weight loss. We screen total T, free T, SHBG, LH/FSH, estradiol. Treat to functional/optimal range with cypionate, creams, or pellets — calibrated to the individual. Patients on TRT consistently lose more body fat and preserve more lean mass on GLP-1 therapy than untreated hypogonadal men.
BHRT (Women)
Estradiol, progesterone, and (for many) testosterone optimized to functional ranges. Perimenopausal and post-menopausal weight gain is largely a hormone story; treating the hormones is often more effective than treating the weight.
BPC-157 + TB-500
Recovery and tissue-repair stack. Why it matters for weight loss: increased training volume causes injury risk in patients new to resistance training. BPC-157 + TB-500 keeps you training. Returned to legal Category 1 status April 23, 2026.
AOD-9604 (limited use)
Modified GH fragment investigated for fat-loss effects. Less robust evidence base than the peptides above, used selectively for patients with stubborn subcutaneous fat that has not responded to first-line interventions. Not a default add-on. Discussed case-by-case.
The non-pharmacologic levers that decide outcomes.
- Protein floor. 1.6–2.2 g/kg of ideal body weight, daily. This is the single most important nutritional lever during GLP-1 therapy. Without adequate protein, lean mass loss accelerates and the metabolic damage outlasts the weight loss.
- Resistance training. Minimum 3 sessions per week, full-body, with progressive overload. We provide a starter protocol in the patient portal and can refer to local coaches in Dalton, Calhoun, and Chattanooga. Cardio is a complement; it is not a replacement.
- Sleep architecture. 7–8 hours, dark room, consistent timing, sleep apnea ruled out. CGM data routinely shows worse glucose and ghrelin patterns the day after < 6 hours of sleep. The drug doesn't beat that.
- Alcohol calibration. Alcohol calories displace protein, disrupt sleep, and impair recovery. We are not abstinence-mandating; we are informed-consent giving.
- Hydration and electrolytes. GLP-1 therapy frequently produces dehydration and electrolyte imbalances that get blamed on the drug when they are correctable in 48 hours. We coach this proactively.
- Continuous glucose monitoring (selectively). CGM is not for everyone, but for the patient who wants real-time feedback on food, exercise, and stress, it accelerates self-knowledge significantly.
How protocols come together — three illustrative pictures.
The 47-year-old executive, 35 lbs to lose, no comorbidities
Tirzepatide titrated to 10 mg. Testosterone optimized (TRT). MOTS-c 6-week cycle in month 4. NAD+ loading. Resistance training 3×/week with creatine and 1.8 g/kg protein. CGM during the first 90 days for feedback. Plan: 18-month cut, taper, maintenance.
The 53-year-old post-menopausal woman, 25 lbs to lose, scale stuck
BHRT first (estradiol, progesterone, testosterone). Often, hormone correction alone moves 10–15 lbs over 4 months. If still stuck at month 4, low-dose semaglutide added. Tesamorelin layered for visceral fat. NAD+. Strength training and protein architecture mandatory.
The patient who already lost 60 lbs and stopped tirzepatide six months ago
Restart strategy if regain has begun: low-dose tirzepatide as maintenance (often 5 mg). MOTS-c for metabolic re-architecture. Hormone audit. Aggressive resistance training and protein. Goal is not to lose weight — goal is to hold position while building the metabolic chassis that should have been built the first time.
The full toolkit, asked and answered.
- Do I have to use a GLP-1 to lose weight?
- No. For BMI < 30 with no metabolic disease, drug therapy is rarely the right first lever. Hormone optimization, sleep correction, resistance training, and protein architecture move significant weight in many patients without any GLP-1.
- Can peptides replace GLP-1 therapy?
- For most patients targeting >10% weight loss, no. The mechanism of action is fundamentally different — peptides shift body composition, GLP-1s reduce caloric intake and improve glycemic control. They are complementary, not interchangeable.
- What about thyroid support?
- Subclinical hypothyroidism is common and underdiagnosed. We screen TSH, free T4, free T3, and reverse T3 — not just TSH alone. Treating with levothyroxine or T4/T3 combination when indicated frequently unsticks weight loss that has been blamed on the GLP-1.
- What's a realistic timeline for results without drugs?
- Hormone optimization typically shows scale results at 60–90 days, body composition results at 4–6 months. Peptide-only protocols vary widely. Drug therapy moves the needle faster, which is why most patients combine.
- Do I need a CGM?
- Not required. Useful for the patient who wants high-resolution feedback on food, sleep, exercise, and stress. We loan a 14-day CGM during the first 90 days when relevant.
- Will my insurance cover any of this?
- Insurance covers semaglutide and tirzepatide variably (depending on plan and BMI/diabetes status). Insurance does not cover peptide therapy, hormone optimization labs beyond standard panels, NAD+, or most concierge-level services. Limitless is fee-for-service. We help you maximize your insurance benefit on what is coverable and quote out-of-pocket transparently for everything else.
Continue the weight-loss series.
The drug is the tool. The system is the result.
Limitless designs comprehensive weight-loss programs — hormones, peptides, training, nutrition, and (when indicated) GLP-1 therapy — calibrated to your labs, history, and goals.
Request a consultation Call Dalton IPC 706-847-0826